Targeting a specific receptor in breast cancer that resists standard treatments
Targeting Constitutively Active SUMO Modified Androgen Receptors in Endocrine Resistant Breast Cancer
This study is looking at a type of breast cancer that doesn't respond to regular hormone treatments, and it's exploring how these cancer cells use different pathways to grow; the goal is to find a new way to treat this cancer by targeting specific receptors that help it survive.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10865140 on NIH RePORTER |
What this research studies
This research focuses on patients with a type of breast cancer that does not respond to standard hormone therapies. It investigates how these resistant cancer cells switch to using androgen receptors for growth and spread. The study aims to develop a new treatment strategy that targets these androgen receptors, particularly by addressing a unique modification that allows them to evade existing therapies. By understanding the role of a specific enzyme in this process, the research seeks to improve treatment outcomes for patients with this challenging form of breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with luminal hormone receptor positive breast cancer who have not responded to conventional endocrine therapy.
Not a fit: Patients with other types of breast cancer or those who have not undergone endocrine therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with endocrine-resistant breast cancer.
How similar studies have performed: Other research has shown promise in targeting androgen receptors in advanced breast cancer, but this specific approach is novel.
Where this research is happening
Houston, United States
- University of Houston — Houston, United States (Active)
Researchers
- Principal investigator: Bawa-Khalfe, Tasneem — University of Houston
- Study coordinator: Bawa-Khalfe, Tasneem
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.